Thursday, February 06, 2025 1:02:22 PM
ILT,
A lot of hidden mysteries about DCVax. I can give you some illustrations.
The combo patent was assigned to NIH, HHS, and the US government. What did they do with the combo patent?
https://patents.google.com/patent/US20150202291A1/en
This gentleman who was involved in the moonshot and responsible for the mission to characterize 8,000 cancers integrating proteogenomics, clinical data, patient reported outcomes, and imaging features. Did we see the data of proteomics analysis on 8000 cancer cases?
https://cme.inova.org/2024-inova-fairfax-ob-gyn-oncology-tumor-board-conference/node/3923/bio/12468/view
The person who is so excited about the curing diseases which were absolutely intractable and not survivable and one month later she suddenly resigned.
“We’re curing people of diseases that we previously thought were absolutely intractable and not survivable,” said Karen Knudsen, CEO of the American Cancer Society and the American Cancer Society Cancer Action Network.
https://apnews.com/article/biden-cancer-moonshot-new-orleans-event-df375e5e4dd1511276710b192bad9c0a
https://pressroom.cancer.org/releases?item=1350
Did the back-and-forth change on the completion date of the combo trial happen around the same time interval? Is it just coincidental? Maybe not.
https://clinicaltrials.gov/study/NCT04201873?term=atl-dc&rank=1&tab=history&a=11#version-content-panel
https://clinicaltrials.gov/study/NCT04201873?term=atl-dc&rank=1&tab=history&a=13#version-content-panel
A lot of hidden mysteries about DCVax. I can give you some illustrations.
The combo patent was assigned to NIH, HHS, and the US government. What did they do with the combo patent?
https://patents.google.com/patent/US20150202291A1/en
This gentleman who was involved in the moonshot and responsible for the mission to characterize 8,000 cancers integrating proteogenomics, clinical data, patient reported outcomes, and imaging features. Did we see the data of proteomics analysis on 8000 cancer cases?
https://cme.inova.org/2024-inova-fairfax-ob-gyn-oncology-tumor-board-conference/node/3923/bio/12468/view
The person who is so excited about the curing diseases which were absolutely intractable and not survivable and one month later she suddenly resigned.
“We’re curing people of diseases that we previously thought were absolutely intractable and not survivable,” said Karen Knudsen, CEO of the American Cancer Society and the American Cancer Society Cancer Action Network.
https://apnews.com/article/biden-cancer-moonshot-new-orleans-event-df375e5e4dd1511276710b192bad9c0a
https://pressroom.cancer.org/releases?item=1350
Did the back-and-forth change on the completion date of the combo trial happen around the same time interval? Is it just coincidental? Maybe not.
https://clinicaltrials.gov/study/NCT04201873?term=atl-dc&rank=1&tab=history&a=11#version-content-panel
https://clinicaltrials.gov/study/NCT04201873?term=atl-dc&rank=1&tab=history&a=13#version-content-panel
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
